Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
暂无分享,去创建一个
Jing Cui | Elizabeth W Karlson | Dana Horakova | Joachim Reischl | Christoph Pohl | Lori B Chibnik | E. Karlson | L. Chibnik | D. Hafler | E. Havrdová | P. Jager | J. Cui | C. Aubin | A. Ascherio | J. Reischl | C. Pohl | K. Simon | D. Horáková | M. Týblová | David A Hafler | Rupert Sandbrink | Alberto Ascherio | R. Sandbrink | Philip L De Jager | Eva Havrdova | J. Heubach | S. Lehr | Stephan Lehr | K Claire Simon | Cristin Aubin | David Bauer | Jürgen F Heubach | Michaela Tyblova | Petra Lelkova | P. Lelková | David Bauer | P. L. Jager | Petra Lelková
[1] A. Compston,et al. Multiple sclerosis. , 2002, Lancet.
[2] Ludwig Kappos,et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci , 2009, Nature Genetics.
[3] Alberto Piazza,et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.
[4] Helen Schuilenburg,et al. Information for : Genome-wide association study and meta-analysis indicates that over 40 loci affect risk of type 1 diabetes , 2009 .
[5] A. Ascherio,et al. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention , 2008, Seminars in neurology.
[6] M. Filippi,et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.
[7] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[8] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[9] M. Filippi,et al. Blockade of chemokine signaling in patients with multiple sclerosis , 2006, Neurology.
[10] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[11] Judy H. Cho,et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.
[12] H. Wiendl,et al. Immunomodulatory treatment strategies in multiple sclerosis , 2008, Journal of Neurology.
[13] D. Goodin,et al. Incidental MRI anomalies suggestive of multiple sclerosis , 2009, Neurology.
[14] L. Nyström,et al. EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study , 2008, Multiple sclerosis.
[15] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[16] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[17] J. Rioux,et al. Integrating risk factors , 2008, Neurology.
[18] David H. Miller,et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.